BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab

NCT ID: NCT00625898

Last Updated: 2020-09-10

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE3
• Total Enrollment: 3509 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-04-30
• Study Completion Date: 2014-07-31

Brief Summary

The trial will determine the value of adding bevacizumab to chemotherapy plus trastuzumab in patients with resected node-positive or high risk node-negative, HER2-positive breast cancer.

Detailed Description

This Phase III, randomized, open-label trial will determine whether the regimens of chemotherapy plus trastuzumab plus bevacizumab improve invasive disease-free survival (IDFS) relative to the regimens of chemotherapy plus trastuzumab. Secondary aims include determining whether the addition of bevacizumab to chemotherapy plus trastuzumab will improve disease-free survival (DFS), overall survival (OS), recurrence-free interval (RFI), and distant recurrence-free interval (DRFI). The benefit of adding bevacizumab for IDFS, DFS, OS, RFI, and DRFI will also be evaluated for each of the two chemotherapy regimens. The cardiac and non-cardiac toxicities of each of the regimens will also be evaluated.

Following local determination that the tumor is HER2-positive for gene amplification by in situ hybridization or is IHC 2+ or 3+, a tumor sample must be submitted for HER2 testing by a designated central laboratory. If central testing confirms that the tumor is HER2-positive (either positive by FISH or IHC 3+) and all other eligibility criteria have been met, the patient will be randomized to a regimen of chemotherapy and trastuzumab with or without bevacizumab.

Patients in the trial will be enrolled in one of two chemotherapy regimen cohorts. One cohort will receive 6 cycles of docetaxel/carboplatin plus trastuzumab (TCH) with or without bevacizumab; the other cohort will receive 3 cycles of docetaxel plus trastuzumab given with or without bevacizumab followed by 3 cycles of 5-Fluorouracil, Epirubicin, Cyclophosphamide (TH-FEC). With both regimens, patients will continue trastuzumab with or without bevacizumab following chemotherapy to complete 1 year of targeted therapy. Following completion of chemotherapy, patients will also receive adjuvant radiotherapy and endocrine therapy as clinically indicated.

The trial will be conducted by investigators affiliated with the Cancer International Research Group (CIRG) and the National Surgical Adjuvant Breast and Bowel Project (NSABP). CIRG and NSABP investigators will only enroll patients in the TCH regimen cohort. Additional investigators, referred to in the protocol as Independent Investigators, will enroll patients in both the TCH regimen or the TH-FEC regimen cohort depending on institutional preference for the one regimen that will be used by that institution for the duration of the trial.

Patients will be given the option of allowing their tumor samples to be used for the BETH translational research and correlative science studies. Also, patients will be asked to consent to the submission of blood and serum samples at scheduled time points during the study.

LVEF assessments will be performed before study entry and then at scheduled time points during therapy and at 18, 36, and 60 months following randomization.

The planned sample size for the trial is 3,000 patients randomized in the faster accruing cohort and a minimum of 3,500 patients overall.

Conditions

Breast Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

1A: TCH-H

Docetaxel (T), Carboplatin (C), and Trastuzumab (H) followed by Trastuzumab (H)

Group Type: ACTIVE_COMPARATOR

Docetaxel

Intervention Type: DRUG

75 mg/m2 IV on day 1 every 3 weeks for cycles 1-6, Arms 1A and 1B

100 mg/m2 on day 1 every 3 weeks for cycles 1-3, Arms 2A and 2B

Trastuzumab

Intervention Type: DRUG

First dose: 8 mg/kg IV on day 1 of cycle 1 only. Subsequent doses: 6 mg/kg IV on day 1 every 3 weeks for cycles 2-6. Following completion of chemotherapy cycles: 6 mg/kg IV every 3 weeks until 1 year following first trastuzumab dose. Arms 1A and 1B

First dose: 8 mg/kg IV on day 1 of cycle 1 only. Subsequent doses: 6 mg/kg IV on day 1 every 3 weeks for cycles 2-3. 21 days after last dose of FEC: 8 mg/kg IV first post-FEC dose only; subsequent doses 6 mg/kg IV every 3 weeks for a total of 1 year. Arms 2A and 2B

Carboplatin

Intervention Type: DRUG

6 mg/ml/min IV on day 1 every 3 weeks for cycles 1-6

1B: TCHB-HB

Docetaxel (T), Carboplatin (C), Trastuzumab (H), Bevacizumab (B) followed by Trastuzumab (T) and Bevacizumab (B)

Group Type: EXPERIMENTAL

Docetaxel

Intervention Type: DRUG

75 mg/m2 IV on day 1 every 3 weeks for cycles 1-6, Arms 1A and 1B

100 mg/m2 on day 1 every 3 weeks for cycles 1-3, Arms 2A and 2B

Trastuzumab

Intervention Type: DRUG

First dose: 8 mg/kg IV on day 1 of cycle 1 only. Subsequent doses: 6 mg/kg IV on day 1 every 3 weeks for cycles 2-6. Following completion of chemotherapy cycles: 6 mg/kg IV every 3 weeks until 1 year following first trastuzumab dose. Arms 1A and 1B

First dose: 8 mg/kg IV on day 1 of cycle 1 only. Subsequent doses: 6 mg/kg IV on day 1 every 3 weeks for cycles 2-3. 21 days after last dose of FEC: 8 mg/kg IV first post-FEC dose only; subsequent doses 6 mg/kg IV every 3 weeks for a total of 1 year. Arms 2A and 2B

Carboplatin

Intervention Type: DRUG

6 mg/ml/min IV on day 1 every 3 weeks for cycles 1-6

Bevacizumab

Intervention Type: DRUG

15 mg/kg IV on day 1 every 3 weeks for cycles 1-6. Following completion of chemotherapy cycles: 15 mg/kg IV on day 1 every 3 weeks until 1 year following first bevacizumab dose. Arm 1B

15 mg/kg IV on day 1 every 3 weeks for cycles 1-3. 21 days after the last dose of FEC: 15 mg/kg IV on day 1 every 3 weeks until 1 year following first bevacizumab dose. Arm 2B

2A: TH-FEC-H

Docetaxel (T) and Trastuzumab (H) followed by 5-fluorouracil (F), Epirubicin (E), and Cyclophosphamide (C) followed by Trastuzumab (H)

Group Type: ACTIVE_COMPARATOR

Docetaxel

Intervention Type: DRUG

75 mg/m2 IV on day 1 every 3 weeks for cycles 1-6, Arms 1A and 1B

100 mg/m2 on day 1 every 3 weeks for cycles 1-3, Arms 2A and 2B

Trastuzumab

Intervention Type: DRUG

First dose: 8 mg/kg IV on day 1 of cycle 1 only. Subsequent doses: 6 mg/kg IV on day 1 every 3 weeks for cycles 2-6. Following completion of chemotherapy cycles: 6 mg/kg IV every 3 weeks until 1 year following first trastuzumab dose. Arms 1A and 1B

First dose: 8 mg/kg IV on day 1 of cycle 1 only. Subsequent doses: 6 mg/kg IV on day 1 every 3 weeks for cycles 2-3. 21 days after last dose of FEC: 8 mg/kg IV first post-FEC dose only; subsequent doses 6 mg/kg IV every 3 weeks for a total of 1 year. Arms 2A and 2B

5-Fluorouracil

Intervention Type: DRUG

600 mg/m2 IV on day 1 every 3 weeks for cycles 4-6

Epirubicin

Intervention Type: DRUG

90 mg/m2 IV on day 1 every 3 weeks for cycles 4-6

Cyclophosphamide

Intervention Type: DRUG

600 mg/m2 IV on day 1 every 3 weeks for cycles 4-6

2B: THB-FEC-HB

Docetaxel (T), Trastuzumab (H), and Bevacizumab (B) followed by 5-Fluorouracil (F), Epirubicin (E), and Cyclophosphamide (C) followed by Trastuzumab (H) and Bevacizumab (B)

Group Type: EXPERIMENTAL

Docetaxel

Intervention Type: DRUG

75 mg/m2 IV on day 1 every 3 weeks for cycles 1-6, Arms 1A and 1B

100 mg/m2 on day 1 every 3 weeks for cycles 1-3, Arms 2A and 2B

Trastuzumab

Intervention Type: DRUG

First dose: 8 mg/kg IV on day 1 of cycle 1 only. Subsequent doses: 6 mg/kg IV on day 1 every 3 weeks for cycles 2-6. Following completion of chemotherapy cycles: 6 mg/kg IV every 3 weeks until 1 year following first trastuzumab dose. Arms 1A and 1B

First dose: 8 mg/kg IV on day 1 of cycle 1 only. Subsequent doses: 6 mg/kg IV on day 1 every 3 weeks for cycles 2-3. 21 days after last dose of FEC: 8 mg/kg IV first post-FEC dose only; subsequent doses 6 mg/kg IV every 3 weeks for a total of 1 year. Arms 2A and 2B

Bevacizumab

Intervention Type: DRUG

15 mg/kg IV on day 1 every 3 weeks for cycles 1-6. Following completion of chemotherapy cycles: 15 mg/kg IV on day 1 every 3 weeks until 1 year following first bevacizumab dose. Arm 1B

15 mg/kg IV on day 1 every 3 weeks for cycles 1-3. 21 days after the last dose of FEC: 15 mg/kg IV on day 1 every 3 weeks until 1 year following first bevacizumab dose. Arm 2B

5-Fluorouracil

Intervention Type: DRUG

600 mg/m2 IV on day 1 every 3 weeks for cycles 4-6

Epirubicin

Intervention Type: DRUG

90 mg/m2 IV on day 1 every 3 weeks for cycles 4-6

Cyclophosphamide

Intervention Type: DRUG

600 mg/m2 IV on day 1 every 3 weeks for cycles 4-6

Interventions

Docetaxel

75 mg/m2 IV on day 1 every 3 weeks for cycles 1-6, Arms 1A and 1B

100 mg/m2 on day 1 every 3 weeks for cycles 1-3, Arms 2A and 2B

Intervention Type: DRUG

Trastuzumab

First dose: 8 mg/kg IV on day 1 of cycle 1 only. Subsequent doses: 6 mg/kg IV on day 1 every 3 weeks for cycles 2-6. Following completion of chemotherapy cycles: 6 mg/kg IV every 3 weeks until 1 year following first trastuzumab dose. Arms 1A and 1B

First dose: 8 mg/kg IV on day 1 of cycle 1 only. Subsequent doses: 6 mg/kg IV on day 1 every 3 weeks for cycles 2-3. 21 days after last dose of FEC: 8 mg/kg IV first post-FEC dose only; subsequent doses 6 mg/kg IV every 3 weeks for a total of 1 year. Arms 2A and 2B

Intervention Type: DRUG

Carboplatin

6 mg/ml/min IV on day 1 every 3 weeks for cycles 1-6

Intervention Type: DRUG

Bevacizumab

15 mg/kg IV on day 1 every 3 weeks for cycles 1-6. Following completion of chemotherapy cycles: 15 mg/kg IV on day 1 every 3 weeks until 1 year following first bevacizumab dose. Arm 1B

15 mg/kg IV on day 1 every 3 weeks for cycles 1-3. 21 days after the last dose of FEC: 15 mg/kg IV on day 1 every 3 weeks until 1 year following first bevacizumab dose. Arm 2B

Intervention Type: DRUG

5-Fluorouracil

600 mg/m2 IV on day 1 every 3 weeks for cycles 4-6

Intervention Type: DRUG

Epirubicin

90 mg/m2 IV on day 1 every 3 weeks for cycles 4-6

Intervention Type: DRUG

Cyclophosphamide

600 mg/m2 IV on day 1 every 3 weeks for cycles 4-6

Intervention Type: DRUG

Other Intervention Names

Taxotere; Herceptin; Avastin

Eligibility Criteria

Inclusion Criteria

• Life expectancy of at least 10 years, excluding their diagnosis of breast cancer.
• Women who have had breast reconstruction utilizing tissue expanders must be in agreement with delaying surgery to replace the tissue expanders with permanent implants until 3 months following the last dose of bevacizumab
• Women of reproductive potential must agree to use an effective non-hormonal method of contraception (for example condoms, some intrauterine devices, diaphragms, vasectomized partner, or abstinence) during therapy and for at least 6 months after the last dose of bevacizumab and/or trastuzumab.
• Submission of tumor samples from the breast surgery for central HER2 testing is required for all patients prior to enrollment in the BETH Trial
• Signed and dated IRB/EC-approved consent
• ECOG performance status of 0 or 1
• The tumor must be unilateral invasive adenocarcinoma of the breast on histologic examination.
• The breast cancer must be HER2-positive based on test results as follows: Local testing (if available) should demonstrate that the tumor is IHC 2+ or 3+ or is considered to be HER2-positive for gene amplification by FISH, CISH, or other in situ hybridization (ISH) method. If local ISH test results are considered equivocal, the tumor can be submitted for central HER2 testing. (If local testing is not possible, the tumor can be submitted for central HER2 testing.) Central testing (a requirement for ALL patients) must demonstrate that the tumor is HER2-positive which is defined as FISH-positive and/or IHC 3+.
• All of the following staging criteria (according to the 6th edition of the AJCC Cancer Staging Manual) must be met: By pathologic evaluation, primary tumor must be pT1-3; By pathologic evaluation, ipsilateral nodes must be pN0, pN1 (pN1mi, pN1a, pN1b, pN1c), pN2a, pN3a, or pN3b. If pN0, at least one of the following criteria must be met: Pathologic tumor size > 2.0 cm; ER negative and PgR negative; Histologic and/or nuclear grade 2 (intermediate) or 3 (high); or Age < 35 years
• Patients must have undergone either a total mastectomy or breast conserving surgery (lumpectomy).
• For patients who undergo lumpectomy, the margins of the resected specimen must be histologically free of invasive tumor and ductal carcinoma in situ (DCIS) as determined by the local pathologist. If pathologic examination demonstrates tumor at the line of resection, additional operative procedures may be performed to obtain clear margins. If tumor is still present at the resected margin after re-excision(s), the patient must undergo total mastectomy to be eligible. (Patients with margins positive for lobular carcinoma in situ [LCIS] are eligible without additional resection.)
• For patients who undergo mastectomy, margins must be free of gross residual tumor. Patients with microscopic positive margins are eligible.
• Patients must have completed one of the following procedures for evaluation of pathologic nodal status: Sentinel lymphadenectomy followed by removal of additional non-sentinel lymph nodes if the sentinel node (SN) is positive; Sentinel lymphadenectomy alone if pathologic nodal staging based on sentinel lymphadenectomy is pN0, pN1mi or pN1b; or Axillary lymphadenectomy without SN isolation procedure.
• The interval between the last surgery for breast cancer (treatment or staging) and randomization must be at least 28 days but no more than 84 days.
• Patients must have ER analysis performed on the primary tumor prior to randomization. If ER analysis is negative, then PgR analysis must also be performed.
• The most recent postoperative blood counts, performed within 6 weeks prior to randomization, must meet the following criteria: ANC must be greater than or equal to 1200/mm3; Platelet count must be greater than or equal to 100,000/mm3; and Hemoglobin must be greater than or equal to 10 g/dL.
• The following criteria for evidence of adequate hepatic function must be met based on the results of the most recent postoperative tests performed within 6 weeks prior to randomization: total bilirubin must be less than or equal to upper limit of normal (ULN) for the lab unless the patient has a bilirubin elevation > ULN to 1.5 x ULN due to Gilbert's disease or similar syndrome involving slow conjugation of bilirubin; and alkaline phosphatase must be less than or equal to 2.5 x ULN for the lab; and AST must be less than or equal to 1.5 x ULN for the lab. Alkaline phosphatase and AST may not both be > the ULN.
• Patients with AST or alkaline phosphatase > ULN are eligible for inclusion in the study if liver imaging (CT, MRI, PET scan, or PET-CT scan performed within 3 months prior to randomization) does not demonstrate metastatic disease and the requirements for evidence of adequate hepatic function are met.
• Patients with alkaline phosphatase that is > ULN but less than or equal to 2.5 x ULN are eligible for inclusion in the study if a bone scan,PET scan, or PET-CT scan (performed within 3 months prior to randomization) does not demonstrate metastatic disease.
• The following criteria for renal function must be met based on the results of the most recent postoperative tests performed within 6 weeks prior to randomization: Serum creatinine must be less than or equal to ULN for the lab. Measured or calculated creatinine clearance must be > 60 mL/min.
• A urine sample must be tested for protein by determination of the urine protein/creatinine (UPC) ratio or by urine dipstick. UPC ratio must be less than 1.0. Urine dipstick must indicate 0-1+ protein. If dipstick reading is greater than or equal to 2+, determine the UPC ratio, which must be less than 1.0, or collect a 24-hour urine specimen, which must demonstrate < 1.0 g of protein per 24 hours.
• LVEF assessment must be performed within 3 months prior to randomization. The LVEF must be greater than or equal to 55% regardless of the cardiac imaging facility's lower limit of normal (LLN).
• The ECG (performed within 3 months prior to randomization) must not have demonstrated any of the following conditions: ventricular arrhythmias except for benign premature ventricular contractions; supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication; and conduction abnormality requiring a pacemaker.

Exclusion Criteria

• Inflammatory breast cancer.
• Definitive clinical or radiologic evidence of metastatic disease. (Chest imaging [mandatory for all patients] and other imaging [if required] must have been performed within 3 months prior to randomization.)
• Synchronous or previous contralateral invasive breast cancer (Patients with synchronous or previous contralateral DCIS or LCIS are eligible).
• History of ipsilateral invasive breast cancer regardless of treatment or ipsilateral DCIS treated with excision and RT. (Patients with history of ipsilateral LCIS are eligible.)
• History of non-breast malignancies within the 5 years prior to study entry, except for the following: carcinoma in situ of the cervix, carcinoma in situ of the colon, melanoma in situ, and basal cell and squamous cell carcinomas of the skin.
• Previous therapy with anthracyclines, taxanes, carboplatin, trastuzumab, or bevacizumab for any malignancy.
• RT, chemotherapy, and/or targeted therapy, administered for the currently diagnosed breast cancer prior to randomization.
• Continued therapy with any hormonal agent such as raloxifene or tamoxifen (or other SERM) or an aromatase inhibitor. (Patients are eligible if these medications are discontinued prior to randomization.)
• Any sex hormonal therapy, e.g., birth control pills, ovarian hormone replacement therapy, etc. Patients are eligible if these medications are discontinued prior to randomization.
• Cardiac disease (history of and/or active disease) that would preclude the use of the drugs included in the treatment regimens. This includes but is not confined to: Active cardiac disease - angina pectoris that requires the use of anti-anginal medication; ventricular arrhythmias except for benign premature ventricular contractions; supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication; conduction abnormality requiring a pacemaker; valvular disease with documented compromise in cardiac function; and symptomatic pericarditis. History of cardiac disease - myocardial infarction documented by elevated cardiac enzymes or persistent regional wall abnormalities on assessment of LV function; history of documented CHF; and documented cardiomyopathy.
• Uncontrolled hypertension defined as systolic blood pressure (BP) > 150 mmHg or diastolic BP > 90 mmHg, with or without anti-hypertensive medication. (BP must be assessed within 28 days prior to randomization.) Patients with initial BP elevations are eligible if initiation or adjustment of BP medication lowers pressure to meet entry criteria.
• History of hypertensive crisis or hypertensive encephalopathy.
• History of TIA or CVA.
• History of any arterial thrombotic event within 12 months before randomization.
• Symptomatic peripheral vascular disease.
• Intrinsic lung disease resulting in dyspnea.
• Unstable diabetes mellitus.
• Active infection or chronic infection requiring chronic suppressive antibiotics.
• Any significant bleeding within 6 months before randomization, exclusive of menorrhagia in premenopausal women.
• Non-healing wound, skin ulcers, or incompletely healed bone fracture.
• Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to planned start of study therapy.
• Anticipation of need for major surgical procedures during study therapy and for at least 3 months following completion of bevacizumab.
• Gastroduodenal ulcer(s) documented by endoscopy to be active within 6 months before randomization.
• History of GI perforation, abdominal fistulae, or intra-abdominal abscess.
• Known bleeding diathesis or coagulopathy.
• Requirement for therapeutic doses of coumadin or equivalent.
• Sensory/motor neuropathy greater than or equal to grade 2, as defined by the NCI CTCAE v3.0.
• Conditions that would prohibit administration of corticosteroids.
• Chronic daily treatment with corticosteroids (dose of > 10 mg/day methylprednisolone equivalent) (excluding inhaled steroids).
• History of hypersensitivity reaction to drugs formulated with polysorbate 80.
• Pregnancy or lactation at the time of study entry. (Note: Pregnancy testing must be performed within 14 days prior to randomization according to institutional standards for women of child-bearing potential.)
• Other non-malignant systemic disease that would preclude the patient from receiving study treatment or would prevent required follow-up.
• Psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would preclude the patient from meeting the study requirements.
• Use of any investigational product within 4 weeks prior to enrollment in the study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Cancer International Research Group (CIRG)

OTHER

Sponsor Role: collaborator

Hoffmann-La Roche

INDUSTRY

Sponsor Role: collaborator

Genentech, Inc.

INDUSTRY

Sponsor Role: collaborator

NSABP Foundation Inc

NETWORK

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Norman Wolmark, MD

Role: PRINCIPAL_INVESTIGATOR

NSABP Foundation Inc

Locations

University of Alabama at Birmingham

Birmingham, Alabama, United States

Clearview Cancer Institute-Decatur

Decatur, Alabama, United States

Clearview Cancer Institute

Huntsville, Alabama, United States

Clearview Cancer Institute- Huntsville

Huntsville, Alabama, United States

Northern Arizona Hematology & Onclogy Associates

Flagstaff, Arizona, United States

Northern Arizona Hematology & Oncology Associates

Sedona, Arizona, United States

Central Hematology/Oncology Medical Group, Inc.

Alhambra, California, United States

Comprehensive Blood and Cancer Center

Bakersfield, California, United States

Kaiser Permanente-Baldwin Park

Baldwin Park, California, United States

Kaiser Permanente-Bellflower

Bellflower, California, United States

Providence Saint Joseph Medical Center

Burbank, California, United States

Hematology-Encinitas

Encinitas, California, United States

Scripps Clinic Encinitas

Encinitas, California, United States

Kaiser Permanente-Fontana

Fontana, California, United States

St. Jude Heritage Healthcare

Fullerton, California, United States

Breastlink Medical Group, Inc

Hawthorne, California, United States

Pacific Shores Medical Group

Huntington Beach, California, United States

Kaiser Permanente-Irvine

Irvine, California, United States

Hematology-La Jolla

La Jolla, California, United States

Sabina R. Wallach, MD., AMC

La Jolla, California, United States

Scripps Cancer Center-San Diego

La Jolla, California, United States

Antelope Valley Cancer Center

Lancaster, California, United States

Kaiser Permanente-Sunset

Los Angeles, California, United States

Kaiser Permanente-West Los Angeles

Los Angeles, California, United States

Kaiser Permanente-Oakland

Oakland, California, United States

North County Oncology Medical Clinic, Inc.

Oceanside, California, United States

Kaiser Permanente-Panorama City

Panorama City, California, United States

Kaiser Permanente-Orange County

Panorama City, California, United States

Wilshire Oncology Medical Group

Pasadena, California, United States

Cancer Care Associates Medical Group, Inc.

Redondo Beach, California, United States

Kaiser Permanente-Riverside

Riverside, California, United States

Kaiser Permanente-Roseville

Roseville, California, United States

Sutter Roseville Medical Center

Roseville, California, United States

Kaiser Permanente-Sacramento

Roseville, California, United States

Sutter Medical Center

Sacramento, California, United States

Sutter Medical Group

Sacramento, California, United States

Peter T. Reissman, MD, Inc

San Diego, California, United States

William Stanton, MD, Inc

San Diego, California, United States

Kaiser Permanente-San Diego

San Diego, California, United States

Sharp Rees-Stealy

San Diego, California, United States

Scripps Clinic-Rancho Bernardo

San Diego, California, United States

Kaiser Permanente-San Francisco

San Francisco, California, United States

Kaiser Permanente-Hayward

San Francisco, California, United States

Sansum Clinic

Santa Barbara, California, United States

Santa Barbara Hematology Oncology Medical Group

Santa Barbara, California, United States

Kaiser Permanente-Santa Clara

Santa Clara, California, United States

Central Coast Medical Oncology Corporation

Santa Maria, California, United States

Kaiser Permanente-South San Francisco

South San Francisco, California, United States

Stanford University Medical Center

Stanford, California, United States

UCLA/Santa Clarita Valley Cancer Center

Valencia, California, United States

Kaiser Permanente-Vallejo

Vallejo, California, United States

San Diego Pacific Oncology & Hematology-Vista

Vista, California, United States

Kaiser Permanente-Walnut Creek

Walnut Creek, California, United States

Kaiser Permanente-Woodland Hills

Woodland Hills, California, United States

University of Colorado Cancer Center

Aurora, Colorado, United States

Penrose Cancer Center

Colorado Springs, Colorado, United States

Kaiser Permanente-Franklin

Denver, Colorado, United States

Cypress Hematology/Oncology

Denver, Colorado, United States

Rocky Mountain Cancer Center - Midtown

Denver, Colorado, United States

CCOP-Colorado Cancer Research Prog. Inc.(Administrative Only)

Denver, Colorado, United States

Shaw Regional Cancer Center

Edwards, Colorado, United States

North Colorado Medical Center

Greeley, Colorado, United States

Kaiser Permanente Rock Creek

Lafayette, Colorado, United States

McKee Medical Center

Loveland, Colorado, United States

Exempla Lutheran Medical Center

Wheat Ridge, Colorado, United States

Oncology Associates P.C.-Avon

Avon, Connecticut, United States

Medical Specialists of SWIM

Bridgeport, Connecticut, United States

Bridgeport Hospital

Bridgeport, Connecticut, United States

Medical Specialists of Fairfield

Fairfield, Connecticut, United States

Oncology Associates of Bridgeport-Fairfield

Fairfield, Connecticut, United States

Hartford Hospital

Hartford, Connecticut, United States

Connecticut Multi Specialty Group-Hartford

Hartford, Connecticut, United States

Oncology Associates P.C.-Hartford

Hartford, Connecticut, United States

Medical Oncology and Hematology, P.C.

Meriden, Connecticut, United States

Eastern Connecticut Hematology & Oncology Associates

Norwich, Connecticut, United States

Black Rock Medical Group

Trumbull, Connecticut, United States

Oncology Associates of Bridgeport-Trumbull

Trumbull, Connecticut, United States

Medical Oncology & Hematology, P.C.

Waterbury, Connecticut, United States

Connecticut Multi Specialty Group-Wethersfield

Wethersfield, Connecticut, United States

Oncology Associates P.C.-Willimantic

Willimantic, Connecticut, United States

CCOP, Christiana Care Health Services Inc.

Newark, Delaware, United States

Washington Cancer Institute

Washington D.C., District of Columbia, United States

Sibley Memorial Hospital

Washington D.C., District of Columbia, United States

Washington Oncology-Hematology Center, PC-Washington

Washington D.C., District of Columbia, United States

Lynn Cancer Institute

Boca Raton, Florida, United States

Florida Cancer Specialists-Bonita Springs

Bonita Springs, Florida, United States

Florida Cancer Specialists-Bradenton

Bradenton, Florida, United States

Florida Cancer Specialists, Brandon

Brandon, Florida, United States

Florida Cancer Specialists-Cape Coral Parkway

Cape Coral, Florida, United States

Florida Cancer Specialists-Cape Coral Del Prado

Cape Coral, Florida, United States

Florida Cancer Specialists

Clearwater, Florida, United States

Florida Cancer Specialists-Englewood

Englewood, Florida, United States

Florida Cancer Specialists-Fort Myers Broadway

Fort Myers, Florida, United States

Florida Cancer Specialists-Fort Myers Summerlin

Fort Myers, Florida, United States

Robert R. Carroll, MD, PA

Gainesville, Florida, United States

Integrated Community Oncology Network

Jacksonville, Florida, United States

Lakeland Regional Cancer Center

Lakeland, Florida, United States

Florida Cancer Specialists-Naples Goodlette

Naples, Florida, United States

Florida Cancer Specialists-NAPA Ridge

Naples, Florida, United States

Integrated Community Oncology Network

Orange Park, Florida, United States

Florida Hospital Cancer Institute

Orlando, Florida, United States

Florida Cancer Specialists, Cornerstone

Palm Harbor, Florida, United States

Florida Cancer Specialists-Port Charlotte

Port Charlotte, Florida, United States

Florida Cancer Specialist-Cattleman

Sarasota, Florida, United States

Florida Cancer Specialists-Downtown

Sarasota, Florida, United States

Florida Cancer Specialists-Park Place

St. Petersburg, Florida, United States

Florida Cancer Specialists

Tampa, Florida, United States

Florida Cancer Specialists

Tampa, Florida, United States

Florida Cancer Specialists-Venice Island

Venice, Florida, United States

Florida Cancer Specialists-Venice

Venice, Florida, United States

Palm Beach Cancer Institute

West Palm Beach, Florida, United States

Phoebe Putney Memorial Hospital

Albany, Georgia, United States

Northeast Georgia Cancer Care, LLC

Athens, Georgia, United States

Grady Healthsystem

Atlanta, Georgia, United States

Emory University

Atlanta, Georgia, United States

Augusta Oncology Associates

Augusta, Georgia, United States

Northwest Georgia Oncology Centers PC

Austell, Georgia, United States

Northwest Georgia Oncology Centers PC

Carrollton, Georgia, United States

Northwest Georgia Oncology Centers PC

Cartersville, Georgia, United States

Suburban Hematology-Oncology Associates

Lawrenceville, Georgia, United States

Central Georgia Cancer Care

Macon, Georgia, United States

Georgia Cancer Specialists

Macon, Georgia, United States

Georgia Cancer Specialists

Marietta, Georgia, United States

Suburban Hematology Oncology Associates PC

Snellville, Georgia, United States

Oncare Hawaii, Inc-POB2

Honolulu, Hawaii, United States

Straub Clinic and Hospital

Honolulu, Hawaii, United States

University of Hawaii

Honolulu, Hawaii, United States

Oncare Hawaii, Inc-KMP

Honolulu, Hawaii, United States

Kootenai Cancer Center

Coeur d'Alene, Idaho, United States

Mountain States Tumor Institute

Meridian, Idaho, United States

Mountain States Tumor Institute

Twin Falls, Idaho, United States

Cancer Care & Hematology Specialists of Chicagoland

Arlington, Illinois, United States

MBCCOP, John H. Stroger, JR., Hospital of Cook County-Chicago

Chicago, Illinois, United States

Rush University Medical Center

Chicago, Illinois, United States

Crossroads Cancer Center

Decatur, Illinois, United States

Cancer Care Specialists-Central Illinois

Decatur, Illinois, United States

Decatur Memorial Hospital

Decatur, Illinois, United States

Edward Hospital

Naperville, Illinois, United States

Edward Cancer Center Plainfield

Plainfield, Illinois, United States

Cancer Care and Hematology Specialists of Chicagoland

Winfield, Illinois, United States

Yorkville Family Practice

Yorkville, Illinois, United States

Cancer Care of Southern Indiana

Bloomington, Indiana, United States

Corydon Hospital Medical Plaza

Corydon, Indiana, United States

Elkhart Clinic

Elkhart, Indiana, United States

Michiana Hematology-Oncology, P.C. (Elkhart)

Elkhart, Indiana, United States

Waverly Hematology Oncology

Gary, Indiana, United States

Clark Medical Building

Jeffersonville, Indiana, United States

Howard Regional Health System

Kokomo, Indiana, United States

Michiana Hematology-Oncology, P.C. (LaPorte)

La Porte, Indiana, United States

Cancer Care Center

New Albany, Indiana, United States

Michiana Hematology-Oncology PC

Plymouth, Indiana, United States

Oncology, P.C. Plymouth

Plymouth, Indiana, United States

South Bend Clinic

South Bend, Indiana, United States

Michiana Hematology-Oncology, P.C. (Main Office)

South Bend, Indiana, United States

Northern Indiana Cancer Research Consortium

South Bend, Indiana, United States

Michiana Hematology-Oncology, P.C. Cedar St.

South Bend, Indiana, United States

Providence Medical Group

Terre Haute, Indiana, United States

Hematology and Medical Oncology Consultants-Bettendorf

Bettendorf, Iowa, United States

Hematology and Medical Oncology Consultants-Davenport

Davenport, Iowa, United States

University of Iowa

Iowa City, Iowa, United States

Lawrence Memorial Hospital

Lawrence, Kansas, United States

University of Kentucky Medical Center

Lexington, Kentucky, United States

NortonHealthcare Pavillion

Louisville, Kentucky, United States

Norton Medical Plaza II

Louisville, Kentucky, United States

Norton Medical Plaza West

Louisville, Kentucky, United States

Old Brownsboro Crossing

Louisville, Kentucky, United States

Baton Rouge General Medical Center

Baton Rouge, Louisiana, United States

Eastern Maine Medical Center

Bangor, Maine, United States

Mercy Medical Center

Baltimore, Maryland, United States

Greater Baltimore Medical Center

Baltimore, Maryland, United States

Franklin Square Hospital Center

Baltimore, Maryland, United States

Harry & Jeannette Weinberg Cancer Institute

Baltimore, Maryland, United States

Hematology-Oncology Associates

Baltimore, Maryland, United States

Carolyn Hendricks, MD

Bethesda, Maryland, United States

Suburban Hospital

Bethesda, Maryland, United States

The Office of Frederik Smith

Chevy Chase, Maryland, United States

Washington Oncology-Hematology Center, PC-Chevy Chase

Chevy Chase, Maryland, United States

Associates in Oncology/Hematology

Rockville, Maryland, United States

Peninsula Regional Oncology & Hematology

Salisbury, Maryland, United States

Peninsula Regional Medical Center

Salisbury, Maryland, United States

Holy Cross Hospital

Silver Spring, Maryland, United States

Oncology Care Associates

Wheaton, Maryland, United States

Berkshire Hematology Oncology, P.C.-North Adams

North Adams, Massachusetts, United States

Berkshire Hematology Oncology, P.C.

Pittsfield, Massachusetts, United States

Bixby Medical Center

Adrian, Michigan, United States

CCOP, St. Joseph Mercy Hospital

Ann Arbor, Michigan, United States

Battle Creek Health System

Battle Creek, Michigan, United States

Bay Regional Medical Center

Bay City, Michigan, United States

Dr. Cook and Abramson - Bay City

Bay City, Michigan, United States

St. Joseph Mercy Woodland Health Center

Brighton, Michigan, United States

Josephone Ford Cancer Center

Brownstown, Michigan, United States

Henry Ford Medical Center-Fairlane

Dearborn, Michigan, United States

Henry Ford Hospital

Detroit, Michigan, United States

UP Hematology/Oncology Assoc.-Doctor's Park Family Physicians

Escanaba, Michigan, United States

CCOP Hurley Medical Center

Flint, Michigan, United States

Genesys Hurley

Flint, Michigan, United States

Sing and Arora

Flint, Michigan, United States

Genesys Regional Medical Center

Grand Blanc, Michigan, United States

Grand Rapids Clinical Oncology Program

Grand Rapids, Michigan, United States

Spectrum Health Hospitals

Grand Rapids, Michigan, United States

St. Mary's Health Services

Grand Rapids, Michigan, United States

CCOP, St. John Hospital and Medical Center

Grosse Pointe Woods, Michigan, United States

Portage Internal Medical Associates

Hancock, Michigan, United States

UP Hematology/Oncology Associates

Iron Mountain, Michigan, United States

UP Hematology/Oncology Associates-Gogebic Range

Ironwood, Michigan, United States

West Michigan Cancer Center

Kalamazoo, Michigan, United States

Hematology/Oncology Associates of OH and MI, PC

Lambertville, Michigan, United States

CCOP, Sparrow Health System

Lansing, Michigan, United States

Michigan State University - Breslin Cancer Center

Lansing, Michigan, United States

Hematology Oncology-Lapeer

Lapeer, Michigan, United States

Lapeer Regional Hospital

Lapeer, Michigan, United States

Keewanaw Memorial Hospital

Laurium, Michigan, United States

St. Mary Mercy Hospital - Livonia

Livonia, Michigan, United States

Marquette General Hospital

Marquette, Michigan, United States

Upper Peninsula Hematology/Oncology Associates

Marquette, Michigan, United States

Community Cancer Care Specialists-Mt. Clemens

Mount Clemens, Michigan, United States

Mount Clemens Regional Medical Center

Mount Clemens, Michigan, United States

Hackley Hospital

Muskegon, Michigan, United States

Michiana Hematology-Oncology PC

Niles, Michigan, United States

CCOP, William Beaumont Hospital

Royal Oak, Michigan, United States

CCOP, St. Mary's Medical Center

Saginaw, Michigan, United States

Lakeside Cancer Specialists, PLLC

Saint Joseph, Michigan, United States

Michiana Hematology-Oncology, PC Lakeland

Saint Joseph, Michigan, United States

Chippewa Medical Associates

Sault Ste. Marie, Michigan, United States

Osteopathic Medical Oncology Hematology

Shelby, Michigan, United States

Munson Medical Center

Traverse City, Michigan, United States

CCOP, St. John Macomb Hospital

Warren, Michigan, United States

Henry Ford Medical Center-West Bloomfield

West Bloomfield, Michigan, United States

Metro Health Hospital

Wyoming, Michigan, United States

Minnesota Oncology Hematology-Burnsville

Burnsville, Minnesota, United States

Park Nicollet Clinic

Burnsville, Minnesota, United States

Hubert H. Humphrey Cancer Center - Coon Rapids

Coon Rapids, Minnesota, United States

Minnesota Oncology Hematology-Edina

Edina, Minnesota, United States

Fairview Southdale Medical Oncology Clinic

Edina, Minnesota, United States

Hubert H. Humphrey Cancer Center - Fridley

Fridley, Minnesota, United States

Minnesota Oncology Hematology PA - Maplewood

Maplewood, Minnesota, United States

Minnesota Oncology Hematology-Minneapolis

Minneapolis, Minnesota, United States

Hubert H. Humphrey Cancer Center-Robbinsdale

Robbinsdale, Minnesota, United States

Park Nicollet Health Services

Saint Louis Park, Minnesota, United States

Minnesota Hematology Oncology-St. Paul

Saint Paul, Minnesota, United States

Minnesota Oncology Hematology-Waconia

Waconia, Minnesota, United States

Minnesota Oncology Hematology

Woodbury, Minnesota, United States

University of Tennessee Cancer Institute

Southaven, Mississippi, United States

University of Missouri-Ellis Fischel

Columbia, Missouri, United States

Freeman Cancer Institute

Joplin, Missouri, United States

St. John's Regional Health Center-Joplin

Joplin, Missouri, United States

Saint Luke's Hospital

Kansas City, Missouri, United States

CCOP, Kansas City (Administrative Only)

Kansas City, Missouri, United States

St. John's Regional Health Center

Springfield, Missouri, United States

Cox Health Systems

Springfield, Missouri, United States

Hematology Oncology Centers of the Northern Rockies

Billings, Montana, United States

Comprehensive Cancer Centers of Nevada (Siena)

Henderson, Nevada, United States

University Medical Center of Southern Nevada

Las Vegas, Nevada, United States

Cancer and Blood Specialists- Shadow Lane

Las Vegas, Nevada, United States

Cancer Consultants

Las Vegas, Nevada, United States

Nevada Cancer Institute

Las Vegas, Nevada, United States

Renown Regional Medical Center

Reno, Nevada, United States

Alpine Hematology-Oncology

Reno, Nevada, United States

Summit Medical Group

Berkeley Heights, New Jersey, United States

Drs. Forte, Schleider, Attas and Condemi, PA

Englewood, New Jersey, United States

Cancer Institute of New Jersey at Hamilton

Hamilton, New Jersey, United States

Monmouth Medical Center

Long Branch, New Jersey, United States

Morristown Memorial Hospital

Morristown, New Jersey, United States

Cancer Institute of New Jersey

New Brunswick, New Jersey, United States

University of Medicine and Dentistry of New Jersey

Newark, New Jersey, United States

Newark Beth Israel Medical Center

Newark, New Jersey, United States

Sparta Cancer Treatment Center

Sparta, New Jersey, United States

Overlook Hospital

Summit, New Jersey, United States

New York Oncology Hematology PC-Albany

Albany, New York, United States

NY Oncology Hematology PC at Albany Medical Center

Albany, New York, United States

Amsterdam Community Cancer Program

Amsterdam, New York, United States

Interlakes Oncology & Hematology, P.C.

Canandaigua, New York, United States

Hematology Oncology Assaociates of CNY, CCOP

East Syracuse, New York, United States

NY Oncology Hematology PC-Hudson Carvell Cancer Tx Prog.

Hudson, New York, United States

NY Oncology Hematology PC- Latham- Capital District Oncology Hematology

Latham, New York, United States

Beth Israel Medical Center

New York, New York, United States

St. Luke's-Roosevelt Hospital Center

New York, New York, United States

Riverview Cancer Care Medical Association

Rexford, New York, United States

Hematology Oncology Associates of CNY, CCOP

Rome, New York, United States

University Hospital and Medical Center - SUNY

Stony Brook, New York, United States

University Hospital and Medical Center-SUNY

Stony Brook, New York, United States

Hematology Oncology Assoc. of CNY, CCOP (Comm. General Hospital Satellite Office)

Syracuse, New York, United States

Troy Cancer Treatment Program

Troy, New York, United States

Cancer Care of Western North Carolina

Asheville, North Carolina, United States

CCOP, Mission Hospitals, Inc.

Asheville, North Carolina, United States

Cancer Center of NC at Asheville

Asheville, North Carolina, United States

Carolinas Hematology-Oncology Associates - Tyron St

Charlotte, North Carolina, United States

Carolinas Medical Center - Blumenthal Cancer Center

Charlotte, North Carolina, United States

CCOP Presbyterian Hospital

Charlotte, North Carolina, United States

Mecklenburg Medical Group - Morehead Medical Dr

Charlotte, North Carolina, United States

Mecklenburg Medical Group - Cameron Valley Pkwy

Charlotte, North Carolina, United States

Carolinas Hematology Oncology Associates - Harris Blvd.

Charlotte, North Carolina, United States

Carolinas Hematology-Oncology - John J. Delaney

Charlotte, North Carolina, United States

CCOP, Wayne Memorial Hospital

Goldsboro, North Carolina, United States

Moses Cone Regional Cancer Center

Greensboro, North Carolina, United States

Northwestern Carolina Oncology & Hematology, PA

Hickory, North Carolina, United States

Carolina BioOncology Institute

Huntersville, North Carolina, United States

Akron City Hospital

Akron, Ohio, United States

Akron General Medical Center

Akron, Ohio, United States

Alliance Cancer Center

Alliance, Ohio, United States

Aultman Hospital

Canton, Ohio, United States

Tri County Hematology/Oncology

Canton, Ohio, United States

Kenwood Office

Cincinnati, Ohio, United States

Oncology/Hematology Care Clinical Trials LLC

Cincinnati, Ohio, United States

North Treatment Center - Blue Ash Medical Center

Cincinnati, Ohio, United States

Oncology/Hematology Care Clinical Trials LLC, Cincinnati, OH Blue Ash Med. Cntr. (Administrative Only)

Cincinnati, Ohio, United States

Oncology/Hematology Care Clinical Trials LLC

Cincinnati, Ohio, United States

Case Western Reserve/University Hospitals-Ireland Cancer Cntr.

Cleveland, Ohio, United States

Dayton Physicians-LLC-Hematology & Medical Oncology Division

Dayton, Ohio, United States

Healthplex

Fairfield, Ohio, United States

Dayton Physicians, LLC - Greenville

Greenville, Ohio, United States

Hamilton Office

Hamilton, Ohio, United States

Dayton Clinical Oncology Program-Kettering

Kettering, Ohio, United States

Marian A. Llenado Lee, MD, Inc.

Kettering, Ohio, United States

Northwest Ohio Oncology Center

Maumee, Ohio, United States

UHHS - Chagrin Highlands

Orange, Ohio, United States

UHHS Green Road-Ireland Cancer Center

South Euclid, Ohio, United States

Flower Memorial Hospital

Sylvania, Ohio, United States

Bayview Oncology Associates

Toledo, Ohio, United States

Toledo Clinic

Toledo, Ohio, United States

UHHS Westlake-Ireland Cancer Center

Westlake, Ohio, United States

Northwest Cancer Specialists-Portland

Portland, Oregon, United States

Providence Portland Medical Center

Portland, Oregon, United States

Adventist Medical Center

Portland, Oregon, United States

Northwest Cancer Specialists-Adventist Office

Portland, Oregon, United States

CCOP, Columbia River Oncology

Portland, Oregon, United States

Providence Oncology and Hematology Care Clinic

Portland, Oregon, United States

Providence St. Vincent Medical Center

Portland, Oregon, United States

Lehigh Valley Hospital

Allentown, Pennsylvania, United States

Geisinger Clinic

Danville, Pennsylvania, United States

Hematology Oncology Associates of NE PA

Donora, Pennsylvania, United States

Ephrata Cancer Center at Ephrata Community Hospital

Ephrata, Pennsylvania, United States

UPMC Cancer Centers Arnold Palmer Pavilion-Mountainview

Greensburg, Pennsylvania, United States

UPMC Cancer Centers Arnold Palmer-Oakbrook

Greensburg, Pennsylvania, United States

UPMC Cancer Centers-Indiana

Indiana, Pennsylvania, United States

UPMC Cancer Centers-John P. Murtha Cancer Center

Johnstown, Pennsylvania, United States

UPMC Cancer Centers - McKeesport Hospital

McKeesport, Pennsylvania, United States

Riddle Memorial Hospital

Media, Pennsylvania, United States

UPMC Cancer Centers Arnold Palmer-Mt. Pleasant

Mount Pleasant, Pennsylvania, United States

Kimmel Cancer Center at Jefferson

Philadelphia, Pennsylvania, United States

Cancer Center at Center One

Philadelphia, Pennsylvania, United States

Albert Einstein Healthcare Network

Philadelphia, Pennsylvania, United States

Allegheny General Hospital/Allegheny-Singer Research Institute

Pittsburgh, Pennsylvania, United States

NSABP Foundation, Inc

Pittsburgh, Pennsylvania, United States

University of Pittsburgh

Pittsburgh, Pennsylvania, United States

UPMC Cancer Centers - UPMC St. Margaret

Pittsburgh, Pennsylvania, United States

Hillman Cancer Center

Pittsburgh, Pennsylvania, United States

UPMC Cancer Centers - UPMC Passavant

Pittsburgh, Pennsylvania, United States

Mercy Hospital

Scranton, Pennsylvania, United States

Scranton Hematology Oncology

Scranton, Pennsylvania, United States

Hematology and Oncology Associates

Scranton, Pennsylvania, United States

Mount Nittany Medical Center

State College, Pennsylvania, United States

UPMC Cancer Centers-Uniontown

Uniontown, Pennsylvania, United States

UPMC Cancer Centers - Wexford

Wexford, Pennsylvania, United States

York Hospital

York, Pennsylvania, United States

Thompson Oncology Group-Blount

Knoxville, Tennessee, United States

Thompson Cancer Survival Center-Dowell Springs

Knoxville, Tennessee, United States

Thompson Cancer Survival Center

Knoxville, Tennessee, United States

Thompson Oncology Group-West

Knoxville, Tennessee, United States

The West Clinic

Memphis, Tennessee, United States

Texas Oncology- Sammons CC

Dallas, Texas, United States

The Center for Cancer and Blood Disorders

Fort Worth, Texas, United States

Baylor College of Medicine

Houston, Texas, United States

Ben Taub General Hospital

Houston, Texas, United States

Covenant Health System dba Joe Arrington Cancer Research & Treatment Center

Lubbock, Texas, United States

North Texas Regional Cancer Center

Plano, Texas, United States

Intermountain Medical Center

Murray, Utah, United States

McKay-Dee Hospital

Ogden, Utah, United States

Utah Valley Regional Medical Center

Provo, Utah, United States

LDS Hospital

Salt Lake City, Utah, United States

Dixie Medical Center

St. George, Utah, United States

VCU Massey Cancer Center at Stony Point

Richmond, Virginia, United States

MBCCOP, Virginia Commonwealth University

Richmond, Virginia, United States

Overlake Internal Medicine

Bellevue, Washington, United States

Rockwood Cancer Treatment Center - Sinto Ave

Spokane, Washington, United States

Rockwood Cancer Treatment Center

Spokane, Washington, United States

Southwest Washington Hospital

Vancouver, Washington, United States

Northwest Cancer Specialists-136th Ave

Vancouver, Washington, United States

Northwest Cancer Specialists-134th St.

Vancouver, Washington, United States

West Virginia University Hospitals Inc.

Morgantown, West Virginia, United States

Oncology Alliance-Burlington

Burlington, Wisconsin, United States

Oncology Alliance-Franklin

Franklin, Wisconsin, United States

Oncology Alliance

Glendale, Wisconsin, United States

Aurora BayCare Medical Center

Green Bay, Wisconsin, United States

Oncology Alliance-Kenosha South

Kenosha, Wisconsin, United States

Oncology Alliance-Kenosha North

Kenosha, Wisconsin, United States

CCOP, Marshfield Clinic

Marshfield, Wisconsin, United States

Oncology Alliance-Menomonee Falls

Menomonee Falls, Wisconsin, United States

Oncology Alliance-Mequon

Mequon, Wisconsin, United States

Oncology Alliance-South

Milwaukee, Wisconsin, United States

Oncology Alliance-Racine

Racine, Wisconsin, United States

Oncology Alliance-Waukeska

Waukesha, Wisconsin, United States

Marshfield Clinic Weston Center

Weston, Wisconsin, United States

Breast Clinica de la mama

La Plata, Buenos Aires, Argentina

Hospital Universitario Austral

Presidente Derqui, Buenos Aires, Argentina

Centro Oncologico Rosario (COR)

Rosario, Sante Fe, Argentina

Hospital Britanico de Buenos Aires

Buenos Aires, , Argentina

CEMIC

Buenos Aires, , Argentina

Macarthur Cancer Center

Campbelltown, New South Wales, Australia

St. George Hospital

Kogarah, New South Wales, Australia

Cancer Therapy Center

Liverpool, New South Wales, Australia

North Shore Private Hospital

St Leonards, New South Wales, Australia

Royal North Shore Hospital

St Leonards, New South Wales, Australia

Southern Medical Day Care

Wollongong, New South Wales, Australia

Royal Brisbane & Women's Hospital

Herston, Queensland, Australia

Mater Adult Hospital

South Brisbane, Queensland, Australia

Ashford Cancer Center

Ashford, South Australia, Australia

Flinders Medical Centre

Bedford, South Australia, Australia

Frankston Hospital

Frankston, Victoria, Australia

The Alfred Hospital

Melbourne, Victoria, Australia

Mount Medical Center

Perth, Western Australia, Australia

Berdat Family Comprehensive Cancer Centre

Subiaco, Western Australia, Australia

Krankenhaus Barmherzige Brueder Graz, Medizinische Abteilung

Graz, , Austria

Universitatsfrauenklinik Graz

Graz, , Austria

Medizinische Universitat Graz - Onkologie

Graz, , Austria

AI University Hospital Innsbruck

Innsbruck, , Austria

Bezirkskrankenhaus Kufstein, Innere Medizin

Kufstein, , Austria

Landeskrankenhaus Leoben, Abteilung fur Haemato-Onkologie

Leoben, , Austria

Krankenhaus Barmherzige Schwestern Linz, Kooperative Studiengruppe, Chirurgie

Linz, , Austria

AI Universitätsklinikum der PMU Landeskliniken

Salzburg, , Austria

AKH Vienna

Vienna, , Austria

Medizinische Universitaet Wien-Allgemeines Krankenhaus, Onkologie

Vienna, , Austria

Krankenhaus Hietzing, Gynaekologische Abteilung

Vienna, , Austria

Landeskrankenhaus Voecklabruck, 2. Medizinische Abteilung

Vöcklabruck, , Austria

Klinikum Wels-Grieskirchen, Kooperative Gruppe Wels/4. Medizinische Abteilung

Wels, , Austria

AZ Klina

Brasschaat, , Belgium

C. H. Notre-Dame and Reine Fabiola

Charleroi, , Belgium

Clinique St Pierre

Ottignies, , Belgium

Medical Institute St. Augustinus

Wilrijk, , Belgium

Clinical Centre University of Sarajevo

Sarajevo, , Bosnia and Herzegovina

Centro Goiano de oncologia

Goiânia, Goiás, Brazil

Lifecenter Sistema de Saude S/A

Belo Horizonte, Minas Gerais, Brazil

Instituto Nacional de Cancer

Rio de Janeiro, Rio de Janeiro, Brazil

Clinica Oncologistas Associados

Rio de Janeiro, Rio de Janeiro, Brazil

Assoiacao hospital de caridade de ijui

Ijuí, Rio Grande do Sul, Brazil

Hospital Das Clinicas de Porto Alegre-HCPA

Porto Alegre, Rio Grande do Sul, Brazil

Irmandade da Santa Casa de Misericoria de Porto Alegre Nucleo de Novos Tratamentos

Porto Alegre, Rio Grande do Sul, Brazil

Clinica de Oncologia de Porto Alegre

Porto Alegre, Rio Grande do Sul, Brazil

Fundacao Dr. Amaral Carvalho

Jaú, São Paulo, Brazil

Instituto de Oncologia Clinica de Piracicaba

Piracicaba, São Paulo, Brazil

Centro de Oncologia e Hematologia da Faculdade de Medicina do ABC

Santo André, São Paulo, Brazil

Instituto do Cancer de Sao Paulo

São Paulo, São Paulo, Brazil

Conjunto Hospitalar de Sorocaba

Sorocaba, , Brazil

District Oncology Dispensary Plovdiv

Plovdiv, , Bulgaria

MHAT "Tsaritsa Yoanna-ISUL" EOOD

Sofia, , Bulgaria

Tom Baker Cancer Centre

Calgary, Alberta, Canada

Cross Cancer Institute, Dept of Medicine

Edmonton, Alberta, Canada

Lion's Gate Hospital

North Vancouver, British Columbia, Canada

Dr. H. Bliss Murphy Cancer Centre

St. John's, Newfoundland and Labrador, Canada

William Osler Health Center

Brampton, Ontario, Canada

Credit Valley Hospital

Mississauga, Ontario, Canada

Southlake Regional Health Centre

Newmarket, Ontario, Canada

Ottawa Hospital Regional Cancer Centre

Ottawa, Ontario, Canada

St. Michaels Hospital

Toronto, Ontario, Canada

Humber River Regional Hospital

Weston, Ontario, Canada

Windsor Regional Cancer Centre

Windsor, Ontario, Canada

Hopital Charles LeMoyne

Greenfield Park, Quebec, Canada

Hopital Maisonneuve Rosemont

Montreal, Quebec, Canada

Royal Victoria Hospital

Montreal, Quebec, Canada

Montreal General Hospital

Montreal, Quebec, Canada

Jewish General Hospital

Montreal, Quebec, Canada

Hospital du Sacre-Coeur

Montreal, Quebec, Canada

University of Montreal Hospital Group

Montreal, Quebec, Canada

Centre Hospitalier Affilie Universitaire De Quebec, Hospital du St-Sacrement

Québec, Quebec, Canada

Hospital Regional Rancagua

Rancagua, Región del Libertador General Bernardo O’Higgins, Chile

Chinese Academy of Medical Science

Beijing, , China

The Pla 307 Hospital

Beijing, , China

Chinese PLA General Hospital

Beijing, , China

Jilin Cancer Hospital

Changchun, , China

West China Hospital, Sichuan University

Chengdu, , China

Fuzhou General Hospital of Nanjing Military Area

Fuzhou, , China

Sun Yat-sen University Hospital

Guangzhou, , China

1st Affiliated Hospital of Zhejiang University

Hangzhou, , China

Zhejiang Tumor Hospital

Hangzhou, , China

Tianjin Cancer Hospital

Tianjin, , China

University Hospital Zagreb

Zagreb, , Croatia

FN Na Bulovce

Prague, , Czechia

National Cancer Institute

Cairo, , Egypt

Tartu University Hospital Clinic of Hematology and Oncology

Tartu, , Estonia

CHU D'Amiens

Amiens, , France

CH-Service Hemato-Oncologie

Beauvais, , France

Clinique Bordeaux Nord Aquitaine

Bordeaux, , France

CHU Morvan

Brest, , France

Hopital Pasteur

Colmar, , France

Ch intercommunal de creteil

Créteil, , France

Centre Leonard de Vinci

Dechy, , France

Institut Daniel Hollard

Grenoble, , France

CHD les Oudairies

La Roche-sur-Yon, , France

Clinique Francois Chenieux

Limoges, , France

CHU Dupuytren

Limoges, , France

Hopital St. Joseph

Marseille, , France

Centre Regional de Lutte contre le Cancer (CRLC) Val d'Aurelle

Montpellier, , France

Centre Catherine de Sienne

Nantes, , France

Clinique Hartmann

Neuilly-sur-Seine, , France

CHU Hotel Dieu

Paris, , France

Hopital St. Antoine

Paris, , France

Clinique Saint Hilaire

Rouen, , France

Pole de cancerologie prive

Strasbourg, , France

CLCC Paul Strauss

Strasbourg, , France

Institution Claudius Regaud

Toulouse, , France

Polyclinique du Parc

Toulous, , France

Klinikum St. Marien Amberg

Amberg, , Germany

Hochwaldkrankenhaus

Bad Nauheim, , Germany

Klinikverbund Suedwest - Sindelfingen-Böeblingen Clinical Centre

Böeblingen, , Germany

Klinikum Chemnitz

Chemnitz, , Germany

Universitaetsklinikum Dresden

Dresden, , Germany

Luisenkrankenhaus

Düsseldorf, , Germany

Universitaetsfrauenklinik

Essen, , Germany

Zentrum fur Frauenheilkunde und Geburtshilfe

Frankfurt, , Germany

Medizinisches Versorgungszentrum Osthessen

Fulda, , Germany

Kreiskrankenhaus Hameln

Hamelin, , Germany

Klinikum Stadt Hanau

Hanau, , Germany

Klinikum Hannover Nordstadt

Hanover, , Germany

Universitat Frauenklinik Jena

Jena, , Germany

Onkologische schwerpunktpraxis

Leer, , Germany

Klinikum Lippe Lemgo

Lemgo, , Germany

Asklepios Kliniken Lich GmbH

Lich, , Germany

Universitaetsklinikum Mainz

Mainz, , Germany

St. Vincenz u. Elisabeth Hospital

Mainz, , Germany

Ev Krankenhaus Bethesda

Mönchengladbach, , Germany

RotKreuzKlinikum München GmbH

Munich, , Germany

Universitaetsklinikum Munster

Münster, , Germany

Praxis und Tagesklinik fuer Onkologie und

Recklinghausen, , Germany

Klinikum Rosenheim

Rosenheim, , Germany

Klinikum Schaumburg

Stadhagen, , Germany

Johanniter Krankenhaus

Stendal, , Germany

Robert-Bosch-Krankenhaus

Stuttgart, , Germany

Fachärzte fürlnnere Medizin, Hämatologie

Traunstein, , Germany

P.G. Hospital of Thessaloniki "Papageorgiou"

Thessaloniki, , Greece

Prince of Wales Hospital

Hong Kong, , Hong Kong

Queen Elizabeth Hospital

Hong Kong, , Hong Kong

Semmelweis Egyetem Clinic of Radiology

Budapest, , Hungary

DEOEC Onkologiai Tanszek

Debrecen, , Hungary

Petz Aladar Megyei Oktato

Győr, , Hungary

Kaposi Mor oktato korhaz Onkologiai tanszek

Kaposvár, , Hungary

Cork University Hospital

Cork, , Ireland

Beaumont Hospital

Dublin, , Ireland

St. James's Hospital

Dublin, , Ireland

Adelaide and Meath National Childrens Hospital

Dublin, , Ireland

Institute for Cancer Research

Dublin, , Ireland

Mater Private Hospital

Dublin, , Ireland

St. Vincent's University Hospital

Dublin, , Ireland

University College Hospital Galway

Galway, , Ireland

Midwestern Regional Hospital

Limerick, , Ireland

Sligo General Hospital

Sligo, , Ireland

The Lady Davis Carmel Medical Center/Lynn

Haifa, , Israel

Meir Medical Center

Kfar, , Israel

Kaplan Medical Center

Rehovot, , Israel

Ziv Medical Center

Safed, , Israel

Sourasky (Ichilov) Medical Center

Tel Aviv, , Israel

Assaf Harofeh Medical Center

Ẕerifin, , Israel

Humanitas Centro Catanese

Catania, , Italy

(Azienda u.s.I. chieti) - Policinico Ospedaliero

Chieti, , Italy

Ospedale vito fazzi

Lecce, , Italy

Ospedale di Mirano

Mirano, , Italy

IRCCS - Instituto Nazionale per lo Studio e la Cura

Napoli, , Italy

Fondazione Salvatore Maugeri

Pavia, , Italy

Ospedale S. Filippo Neri

Roma, , Italy

Regina Elena Cancer Institute

Rome, , Italy

Ospedale casa sollievo della sofferenza

San Giovanni, , Italy

Universita-istituto Clinica Medica

Sassari, , Italy

Asl n. 5 -Ospedale s. Vincenzo

Taormina, , Italy

P. Stradina Clinical University Hospital

Riga, , Latvia

Opcion Oncologia

Monterrey, , Mexico

Hospital Nacional Carlos Alberto Seguin

Arequipa, , Peru

Hospital Nacional Edgardo Rebagliati Martins

Lima, , Peru

Cebu Doctors University Hospital

Cebu City, , Philippines

Regional Oncology Center

Bialystok, , Poland

Centrum Onkologii Instytut im. M.

Gliwice, , Poland

ZOZ MSWiA z Warminsko-Mazurskim Centrum

Olsztyn, , Poland

Olsztynski Osrodek Onkologiczny "Kopernik"

Olsztyn, , Poland

Samodzielny Publiczny Zaklad Opieki

Rybnik, , Poland

Breast Cancer Clinic

Warsaw, , Poland

HUC

Coimbra, , Portugal

IPO Francisco Gentil-Porto

Porto, , Portugal

County Hospital Alba-Iulia

Alba Iulia, , Romania

Institute of Oncology "AI.Trestioreanu"

Bucharest, , Romania

Institutul Oncologic "Prof. Dr. I. Chiricuta" Cluj-Napoca

Cluj-Napoca, , Romania

State Medical Institution "Republican Clinical Oncology Dispensary Ministry of Health of Republic Tatarstan"

Kazan', , Russia

State Institution "Russian Oncological Research Center n.a. N.N. Blokhin of RAMS"

Moscow, , Russia

Federal State Institution "Research Institute of Oncology n.a. N.N. Petrov Rosmedtechnologiy"

Saint Petersburg, , Russia

Saint-Petersburg State Medical Institution "City Clinical Oncology Dispensary"

Saint Petersburg, , Russia

Clinical Hospital Center Bezanijska Kosa

Belgrade, , Serbia

Clinic of Oncology, Clinical Center nis

Niš, , Serbia

University Clinical Centre

Maribor, , Slovenia

Department of Oncotherapy National Hospital

Bloemfontein, , South Africa

Hopelands Cancer Centre

Durban, , South Africa

Johannesburg Hospital

Johannesburg, , South Africa

Seoul National University Bundang Hospital

Gyeonggi-do, , South Korea

Seoul National University Hospital

Seoul, , South Korea

Severance Hospital

Seoul, , South Korea

Samsung Medical Center

Seoul, , South Korea

Asan Medical Center

Seoul, , South Korea

Hospital Universitario Insular de Gran Canaria

Las Palmas, Canary Islands, Spain

Complejo Hospitalario Universitario A Coruna

A Coruña, , Spain

Centro Oncologico de Galicia

A Coruña, , Spain

Fundacion Hospitalaria de Alcorcon

Alcorcón, , Spain

Hospital General de Alicante

Alicante, , Spain

Hospital Perpetuo Socorro

Badajoz, , Spain

Hospital Germans Trias l Pujol

Badalona (Barcelona), , Spain

Hospital Comarcal de Barbastro

Barbastro, , Spain

Hospital Del Mar

Barcelona, , Spain

Hospital Santa Crue l San Pau

Barcelona, , Spain

Hospital Clinic i Provincial

Barcelona, , Spain

Consorci Sanitari de Terrassa

Barcelona, , Spain

Althaia Xarxa Assistencial de Manresa

Barcelona, , Spain

Hospital Espiritu Santo

Barcelona, , Spain

Hospital De San Pedro de Alcantara

Cáceres, , Spain

Instituto Oncologico de Guipuzcoa

Donostia / San Sebastian, , Spain

Hospital Gral. De Elche

Elche, , Spain

Hospital de Cabueñes, Oncologia Médica

Gijón, , Spain

Instituto Catalan Oncologia de Girona

Girona, , Spain

Complejo Hospitalario de Jaen

Jaén, , Spain

Hospital Xera Calde

Lugo, , Spain

Hospital Universitario Gregorio Maranon

Madrid, , Spain

Hospital Ruber International

Madrid, , Spain

Fundacion Jimenez Diaz

Madrid, , Spain

Hospital Universitario San Carlos

Madrid, , Spain

Centro Integral de Oncologia "Clara Campal"

Madrid, , Spain

Hospital Clinico Virgen de la Victoria

Málaga, , Spain

Hospital Univesitario Carlos Haya

Málaga, , Spain

Hospital Santa Maria Nai Dr. Cabaleiro

Ourense, , Spain

Complejo Hospitalario de Pontevedra

Pontevedra, , Spain

Hospital del Parc Tauli

Sabadell, , Spain

Hospital Universitario de Salamanca

Salamanca, , Spain

Hospital Universitario de Canarias

San Cristóbal de La Laguna, , Spain

Hospital Universitario Virgen del Rocio

Seville, , Spain

Hospital Torrevieja Salud, UTE

Torrevieja, , Spain

Hospital Clinico Universitario de Valencia

Valencia, , Spain

Hospital Clinico Universitario Lozano Blesa

Zaragoza, , Spain

Hospital U. Miguel Servet

Zaragoza, , Spain

Sahlgrenska University Hospital

Gothenburg, , Sweden

Karolinska University Hospital

Stockholm, , Sweden

Changhua Christian Hospital

Changhua, , Taiwan

Kaohsiung Medical University Chung

Kaohsiung City, , Taiwan

National Cheng Kung University

Tainan City, , Taiwan

Sun Yat-Sen Cancer Center

Taipei, , Taiwan

Taipei Veterans General Hospital

Taipei, , Taiwan

Chang Gung Memorial Hospital

Taoyuan District, , Taiwan

Chulalongkorn Hospital

Patumwan, Bangkok, Thailand

National Cancer Institute

Bangkok, , Thailand

Songklanagarind Hospital

Songkhla, , Thailand

Royal Bournemouth Hospital

Bournemouth, , United Kingdom

Bristol Hematology - Oncology Centre

Bristol, , United Kingdom

Ipswich Hospital

Ipswich, , United Kingdom

Christie Hospital NHS Trust

Manchester, , United Kingdom

Nottingham City Hospital

Nottingham, , United Kingdom

Peterborough District Hospital

Peterborough, , United Kingdom

Sunrise Cancer Centre

Truro, , United Kingdom

Countries

United States; Argentina; Australia; Austria; Belgium; Bosnia and Herzegovina; Brazil; Bulgaria; Canada; Chile; China; Croatia; Czechia; Egypt; Estonia; France; Germany; Greece; Hong Kong; Hungary; Ireland; Israel; Italy; Latvia; Mexico; Peru; Philippines; Poland; Portugal; Romania; Russia; Serbia; Slovenia; South Africa; South Korea; Spain; Sweden; Taiwan; Thailand; United Kingdom

Other Identifiers

CIRG (TRIO) 011

Identifier Type: OTHER

Identifier Source: secondary_id

Roche BO20906

Identifier Type: OTHER

Identifier Source: secondary_id

BETH

Identifier Type: OTHER

Identifier Source: secondary_id

NSABP B-44-I

Identifier Type: -

Identifier Source: org_study_id